局部进展期乳腺癌新辅助化疗前后生物标志物表达变化与疗效的相关性  

Correlation of biomarker expression and therapeutic efficiency in locally advanced breast cancer after neoadjuvant chemotherapy

作　　者：石阳[1,2] 李琦[1] 李蓉[3] 田聆[1] 

机构地区：[1]上海交通大学附属第一人民医院(实验中心,肿瘤中心),上海200080 [2]上海市黄浦区中心医院肿瘤内科,上海200002 [3]上海市黄浦区中心医院乳腺外科,上海200002

出　　处：《现代肿瘤医学》2016年第1期59-63,共5页Journal of Modern Oncology

基　　金：上海市黄浦区科技基金资助项目(编号:HKW201449)

摘　　要：目的:探讨局部进展期乳腺癌行新辅助化疗前后相关生物标志物的表达变化情况与化疗疗效的相关性。方法:采用免疫组化方法检测102例新辅助化疗前后局部进展期乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体-2(HER-2)、p53和增殖细胞核抗原(Ki-67)等表达,分析化疗前后生物标志物表达变化与化疗疗效的相关性。结果:ER阴性组、PR阴性组、Ki-67高表达组的新辅助化疗有效率分别为50.0%、49.1%、51.4%,高于ER阳性组26.0%、PR阳性组25.5%、Ki-67低表达组9.4%(P<0.05)。Logistic多因素回归分析显示,ER、Ki-67的表达水平是评估化疗疗效的独立因素(P<0.05)。Luminal型乳腺癌总生存期高于non-Luminal型(Long-rank检验,P<0.05)。结论:ER、Ki-67、分子亚型可作为局部进展期乳腺癌新辅助化疗疗效判断的重要预测指标。Objective ： To evaluate the relation of therapeutic efficiency of locally advanced breast cancer after neoadjuvant chemotherapy with related biomarkers. Methods ： The expression of ER, PR, HER - 2, Io53 and Ki - 67 in clinical tissue samples from 102 patients with locally advanced breast cancer were detected by immunohistochemistry, and analyze the correlation between the biomarker expression and the therapeutic efficiency. Results：The efficiency of the neoadjuvant chemotherapy in ER negative group （ 50.0% ）, PR negative group （ 49.1% ）, Ki - 67 overexpression group （51.4%） were significantly higher than that in ER positive group （26.0%）,PR positive group （25.5%）, Ki-67 low expression group （9.4%） （P 〈0.05 ）. Logistic regression analysis showed that the expression level of ER, Ki -67 was an independent factor for the chemotherapy efficacy. Breast cancer patients with Luminal type have higer overall survival than non - Luminal type （ P 〈 0.05 ）. Conclusion ： ER, Ki - 67 and molecular subtypes can predict the therapeutic efficiency of neoadjuvant chemotherapy in locally advanced breast cancer.

关 键 词：局部进展期乳腺癌 新辅助化疗 生物标志物 分子分型 疗效 

分 类 号：R737.9[医药卫生—肿瘤]